## Strong early impact of letrozole on ovulation induction

- outperforms clomiphene citrate in polycystic ovary
- syndrome: a systematic review with meta-analysis 3

- Rita Zsuzsanna Vajna<sup>1,2</sup>, András Mihály Géczi<sup>1,2</sup>, Fanni Adél Meznerics<sup>2,4</sup>, Nándor Ács<sup>1,2</sup>, 6
- Péter Hegyi<sup>2,5,6</sup>, Emma Zoé Feig<sup>2</sup>, Péter Fehérvári<sup>2,7</sup>, Szilvia Kiss-Dala<sup>2</sup>, Szabolcs Várbíró<sup>1,2</sup>, 7
- 8 Judit Réka Hetthessy<sup>3</sup> ¶, Levente Sára<sup>1,2\*</sup>¶

1

2

4

5

9

10

11

13

15

17

20

22

24

- 1. Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary 12
- 2. Centre for Translational Medicine, Semmelweis University, Budapest, Hungary 14
- 3. Department of Orthopaedics, Semmelweis University, Budapest, Hungary 16
- 4. Department of Dermatology, Venereology and Dermatooncology, Semmelweis 18 19 University, Budapest, Hungary
- 5. Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary 21
- 23 6. Institute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary
- 7. Department of Biomathematics and Informatics, University of Veterinary Medicine, 25 26 Budapest, Hungary
  - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a	CC-BY 4.0	International license.
------------------------------	-----------	------------------------

28	*Corresponding author
29	E-mail: saralevente@icloud.com (LS)
30	
31	
32	¶ Equal contribution, therefore, the authors should be considered as co-last authors
33	
34	
35	Acknowledgments
36	None.
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	

**Conflict of interest** 54 55 None to declare. **CRediT** author contribution statement 56 **RZSV:** conceptualisation, project administration, methodology, formal analysis, writing – 57 original draft; AMG: conceptualisation, data curation, writing - review & editing; FAM: 58 conceptualisation; supervision; writing – original draft; NÁ: conceptualisation, writing – 59 review & editing; PH: conceptualisation, writing - review & editing; EZF: conceptualisation, 60 data curation, writing - review & editing; PF: conceptualization and design of the study, data 61 curation, writing - review & editing; SZK-D: conceptualisation, data curation, writing -62 review & editing; SZV: conceptualisation, formal analysis, visualization, writing – review & 63 editing; JRH: conceptualisation, writing -review & editing; LS: conceptualisation; 64 supervision; writing – original draft 65 **Funding** 

#### 66

- This research did not receive any specific grant from funding agencies in the public, 67
- commercial, or not-for-profit sectors. 68

#### **Disclosure Statement** 69

70 None.

#### 71 **Ethical approval**

- No ethical approval was required for this systematic review with meta-analysis, as all data 72
- were already published in peer-reviewed journals. No patients were involved in the design, 73
- conduct, or interpretation of our study. 74
- The datasets used in this study can be found in the full-text articles included in the systematic 75
- review and meta-analysis. 76

#### **Abstract**

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

Background: Polycystic ovary syndrome is one of the most frequent endocrinological problems causing infertility in women worldwide. The main problem in these women is hyperandrogenism and/or chronic oligo/anovulation, which leads to infertility. In this systematic review and meta-analysis, we aimed to investigate the efficacy of a relatively new drug for ovulation induction, letrozole, by comparing it to the first line of treatment for ovulation induction, clomiphene citrate. Methods: A literary search was conducted in three databases and included randomized clinical trials comparing letrozole and clomiphene citrate for ovulation induction for women with polycystic ovary syndrome. The diagnosis of polycystic ovary syndrome was determined according to the Rotterdam criteria. We pooled data using a random-effects model. **Results:** Our search provided a total of 1,994 articles, of which we included 25 studies. In the letrozole group, endometrial thickness was significantly higher (Mean Difference=1.70, Confidence Interval: 0.55-2.86; Heterogeinity: I<sup>2</sup>=97%, p-value=0.008); odds for ovulation (Odds Ratio=1.8, Confidence Interval: 1.21-2.69; Heterogeinity: I<sup>2</sup>=51%, p-value=0.010) and pregnancy (Odds Ratio=1.96, Confidence Interval: 1.37-2.81; Heterogeinity: I<sup>2</sup>=32%, pvalue=0.002) were significantly higher; the resistance index of subendometrial arteries was significantly lower (Mean Difference=-0.15, Confidence Interval: -0.27- -0.04; Heterogeneity: I<sup>2</sup>=92%, p-value=0.030). **Conclusion:** Women with polycystic ovary syndrome treated with letrozole for ovulation induction had higher ovulation and pregnancy rates, their endometrium became thicker, the resistance index of subendometrial arteries was lower. The lower resistance index of the subendometrial arteries can improve intrauterine circulation, which may provide better circumstances for embryo implantation and development.

Keywords: Chlomiphene citrate; Letrozole; Ovulation induction; Polycystic ovary syndrome; Subendometrial blood flow 

## Introduction

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

Polycystic ovary syndrome (PCOS) is one of the most frequent endocrinological problems causing infertility in women worldwide [1-4]; the prevalence of this disease is between 9 and 18% [5]. The main features of the disease are hyperandrogenism and/or chronic oligo/anovulation, which leads to infertility [6, 7]. Clomiphene citrate (CC) has been used since 1960 as a first-line medication for ovulation induction (OI) for women with PCOS [8, 9]. However, it has some unpleasant and non-dosedependent side effects, such as hot flashes, increase in ovarian size, bloating, nausea and vomiting, breast sensitivity and pain, headaches, hair loss, insomnia, and depression [10]. Because of the longer half-life of CC, pregnancy may not occur despite ovulation, perhaps due to its antiestrogenic effects on the endocervix and the endometrium [5, 8, 11]. Letrozole (LE) is a third-generation aromatase inhibitor, an approved adjuvant when treating estrogen receptor-positive breast cancer. [12-15]. LE does not show anti-estrogenic effects [16, 17] and has minor side effects such as leg cramps and headaches [18, 19]. LE is cleared from the circulation faster, with a shorter half-life compared to CC [8]. The aromatase inhibition develops, endometrium receptors are up-regulated and rapid endometrial growth is observed without adverse effects on endometrium receptivity [8, 15]. Better blood supply to the sub-endometrial halo and to the endometrium results in a thicker endometrial wall, thus maximizing the odds of pregnancy [20]. Despite its many beneficial properties, LE is not vet included in the first-line therapy of PCOS patients and little information is available on its effectiveness. Therefore, we aimed to investigate the efficacy of LE on ovulation rate, endometrial receptivity, and pregnancy rate in women with PCOS compared to the effects of CC by performing a systematic review and meta-analysis.

**Methods** We describe our systematic review and meta-analysis based on the recommendations of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines (S2 Table) [21], while we followed the Cochrane Handbook's recommendations for Systematic Reviews of Interventions Version 6.1.0 [22]. The protocol of the study was registered on PROSPERO (registration number CRD42022376611; see https://www.crd.york.ac.uk/PROSPERO); the protocol was strictly adhered to, additionally, we conducted a post-hoc analysis including 12 additional outcomes indicated in the population-intervention-control-outcome (PICO) to provide a comprehensive overview of all potentially important outcomes. Literature search and eligibility criteria We completed our systematic literature search in three medical databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, from inception to 21 November 2022. We applied the query '(polycystic ovarian syndrome OR PCOS OR Stein-Leventhal syndrome) AND (letrozole OR aromatase inhibitor)' to all fields in the search engines. Neither language nor other restrictions were imposed. Randomized clinical trials (RCTs) comparing LE to CC were included for patients diagnosed with PCOS based on Rotterdam criteria (at least two years after menarche) [23], comparing LE to CC were included. The following PICO agenda was applied: P: women with PCOS I: LE C: CC

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

O: outcomes according to the protocol: endometrial thickness (ET); number of dominant follicles; ovulation rate; pregnancy rate; endometrial volume; additional outcomes: endometrial pattern- and echogenicity; diameter of dominant follicles; rate of mono-and multifollicular development; single and multiple pregnancy rate; live birth rate; miscarriage rate; prevalence of ectopic pregnancies; number of fetal anomalies; endometrial vascularization index, flow index, vascularization flow index and detection rate of endometrial-subendometrial blood flow; resistance index (RI) and pulsatility index (PI) of subendometrial and uterine arteries; systolic velocity/diastolic velocity of subendometrial arteries; biomarker /vascular endothelial growth factor and integrin alpha vß3/ concentrations in uterine fluid Reviews, cases series, cases reports; studies including patients without PCOS diagnosis, girls before menarche, and those within two years past menarche were excluded from the study. Study selection and data collection The selection was performed by two independent reviews (RZSV and EZF). Data from the eligible articles were collected by two authors (RZSV and AMG) independently. The following data were extracted about the study: first author; study type; the year of publications; study population; study period. The following data were extracted about patients studied: age; body mass index; duration of infertility; if ovulation was supported with human chorionic gonadotropin or the luteal phase with progesterone; the time interval for endometrial testing in relation to the cycle; the dose of LE or CC and the time of their administration in relation to the cycle, and data on the outcomes. Study risk of bias assessment Two authors (RZSV and AMG) performed the risk of bias assessment independently. Risk of bias was measured using the Risk of Bias Tool 2 [23], as recommended by the Cochrane

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

Collaboration. The quality assessment of the studies included was accomplished according to the "Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)" workgroup with GRADE-Pro, as recommended by the Cochrane Collaboration [24]. **Synthesis methods** Statistical analysis was conducted using the R 4.1.2. [25] and meta [26] and dmetar packages [27]. Letrozole and clomiphene citrate were compared by calculating the mean differences of endometrial thickness, number of dominant follicles, diameter of dominant follicles, RI of subendometrial artery and PI of subendometrial artery between the intervention and the control groups. Ovulation rate, pregnancy rate, single pregnancy rate, frequency of miscarriages, frequency of monofollicular and mutlifollicular development were also examined. The following outcomes were also analyzed separately in patients who ovulated only: ET, number of dominant follicles, and pregnancy rate. For binary outcomes, odds ratios with 95% confidence intervals (CI) were used as outcome measures. The number of patients and events was extracted or calculated. The results are presented as the odds of an event in the letrozole group compared to the odds of the same event in the clomiphene citrate group. For continuous data, differences in mean values were used with 95% confidence intervals. To calculate mean differences, sample sizes, mean and standard deviation values were extracted from the studies. Mean differences were calculated by extracting the mean values of the clomiphene citrate group from the mean values of the letrozole group.

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

Pooled OR was calculated with the Mantel-Haenszel method [28] and Robins, Greenland, and Breslow [29]. The exact Mantel-Haenszel method [28] (without continuity correction) was used to handle zero cell counts as recommended by Cooper, Hedges, and Valentine [30] and J. Sweeting, J. Sutton, and C. Lambert [31]. Confidence intervals were created with the Paule-Mandel method [32], recommended by Veroniki et al. [33]. In case of 0 cell counts, individual study odds ratios with 95% confidence intervals were calculated by adding 0.5 as continuity correction (it was used only for visualization on forest plots). Pooled mean differences were computed with the inverse variance method. The restricted maximum-likelihood estimator was used with the Q profile method for confidence intervals by Harrer et al. [34] and Veroniki et al. [33]. Hartung-Knapp adjustments were also applied [35] and IntHout, Ioannidis, and Borm [36]. Between-study heterogeneity was assessed with the Higgins and Thompson's I<sup>2</sup> [37] statistic and the Cochrane Q test recommended by Harrer et al. [34]. The I 2 statistic shows what percentage of heterogeneity cannot be explained by random chance. Heterogeneity is considered substantial if I 2 exceeds 75%. **Publication bias and heterogeneity** Publication bias was measured using funnel plots and Egger's test [38, 39]. In case of endometrial thickness and pregnancy rate. The funnel plots do not indicate publication bias and the result of Egger's test was not significant, which means publication bias could not be detected. In case of endometrial thickness, number of dominant follicles and diameter of dominant follicles, RI of subendometrial artery and PI of subendometrial artery substantial heterogeneity could be observed. Other outcome measures showed low or moderate heterogeneity.

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Results Search and selection 223 We found 1,994 articles as a result of our systematic search. After duplicate removal, title 224 and abstract selection was performed on 1274 articles. Finally, we included 22 [1, 4, 15, 16, 225 19, 40-55] studies after full-text selection, and three additional studies based on citation 226 search [5, 6, 56]. The details of the search and selection process are visualized in Fig 1. 227 Characteristics of the included studies 228 229 Baseline and patient characteristics of the studies included in the systematic review and metaanalysis are detailed in **Table 1**. 230 231 232 233 234

Table 1. Basic characteristics of the studies included in the systematic review and meta-analysis

Author (year)	Study site	N° of PP analyzed patients	N° of PP analyzed patients in LE group	N° of PP analyzed patients in CC group	Follow-up period (Number of treatment cycles)	Age (years) in LE group	Age (years) in CC group	BMI (kg/m2) in LE group	BMI (kg/m2) in CC group	Duration of infertility (years) in LE group	Duration of infertility (years) in CC group	Dosage of LE (mg/die)	Dosage of CC (mg/die)	Administration period of LE (day of cycle)	Administration period of LE (day of cycle)	Trigger of ovulation with HCG	Support of luteal phase with progesterone
Studies include	ed in the meta-	-analysis															
Al-Obaidi et al. [15]	Iraq	80	40	40	1	28.45±5.95 ‡ (PP)	29.58±5.81 ‡ (PP)	25.29±2.76 ‡ (PP)	24.87±2.85 ‡ (PP)	3.53±1.87 ‡ (PP)	3.5±1.88 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Atay et al. [40]	Turkey	106	51	55	1	27.1±0.9 ‡ (PP)	26.2±1.1 ‡ (PP)	26.1±1.91 ‡ (PP)	25.8±1.77 ‡ (PP)	2.2±0.7 ‡ (PP)	2.4±0.9 ‡ (PP)	2.5	100	3-7.	3-7.	Y	NA
Dehbashi et al. [56]	Iran	100	50	50	1	23.62±2.92 ‡ (PP)	24.32±3.43 ‡ (PP)	27.45±4.61 ‡ (PP)	27.09±3.61 ‡ (PP)	2±1.34 ‡ (PP)	2.3±1.85 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Elsedeek et al. [4]	Egypt	116	59	57	1	24.95±3.11‡ (PP)	25±3.59 ‡ (PP)	27.7±3.48 ‡ (PP)	29.18±3.47 ‡ (PP)	NA	NA	5	100	3-7.	3-7.	N	NA
Ghahiri et al. [6]	Iran	101	50	51	1	25.63 ± 4.41 (LE + CC group) ‡ (PP)	25.63 ± 4.41 (LE + CC group) ‡ (PP)	28.24±5.2 ‡ (PP)	27.13±4.9 ‡ (PP)	1: 6* (12**); >1: 44* (88**) (PP)	1: 4* (8**); >1: 47* (92**) (PP)	5	100	3-7.	3-7.	NA	NA
Hendawy et al. [41]	Egypt	54	28	26	1	27.2 ± 5.18 ‡ (ITT)	25.21 ± 5.18 ‡ (ITT)	26.2 ± 1.8 ‡ (ITT)	29.1 ± 2.3 ‡ (ITT)	NA	NA	2.5	100	3-7.	3-7.	Y	Y
Hussein et al. [42] ^	Iraq	80	40	40	1	28.45±5.95 ‡ (PP)	29.58±5.81 ‡ (PP)	25.29±2.76 ‡ (PP)	24.87±2.85 ‡ (PP)	3.53±1.87 ‡ (PP)	3.5±1.88 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Kar [43]	India	103	52	51	1	26.26±2.41 ‡ (PP)	26.27±2.47 ‡ (PP)	25.91±3.57 ‡ (PP)	25.95±3.31 ‡ (PP)	3.08±1.92 ‡ (PP)	3.14±2.16 ‡ (PP)	5	100	2-6.	2-6.	Y	Y
Khakhwani et al. [44]	Pakistan	70	36	34	I	<pre>&lt;20: 5* (12.8**); 21- 30: 34* (87.2**) (ITT)</pre>	≤20: 3* (7.7**); 21- 30: 36* (92.3**) (ITT)	<25: 24* (61.5**); >25: 15* (38.5**) (ITT)	<25: 28* (71.8**); >25: 11* (28.2**) (ITT)	<3: 30** (76.9**); ≥3: 9* (23.1**) (ITT)	<3: 30* (76.9**); ≥3: 12* (30.8**) (ITT)	5	100	3-7.	3-7.	NA	NA
Morbusher [45]	Pakistan	100	50	50	1	24.29±2.3 ‡ (PP)	24.26±2.33 ‡ (PP)	25.91±3.32 ‡ (PP)	25.89±3.31 ‡ (PP)	3.18±2.12 ‡ (PP)	3.12±2.02 ‡ (PP)	2.5	100	2-6.	2-6.	Y	Y

Najafi et al. [16]	Iran	220	110	110	1		26.2±3.6 ‡ (PP)	27±3.6 ‡ (PP)	27.6±1.8 ‡ (PP)	27.3±1.8 ‡ (PP)	2.1±1.2 ‡ (PP)	2.4±1.3 ‡ (PP)	10	100	3-7.	3-7.	Y	NA
Selim et al. [19]	Saudi Arabia	201	102	99	1		26±2.7 ‡ (PP)	25.1±3.1 ‡ (PP)	24.4±4.3 ‡ (PP)	23.8±3.7 ‡ (PP)	2.9±0.6 ‡ (PP)	2.6±0.7 ‡ (PP)	5	100	3-7.	3-7.	Y	NA
Wang et al. [1]	China	160	80	80	1		29.2±5.1 ‡ (PP)	28.4±4.6 ‡ (PP)	21.4±3.9 ‡ (PP)	22±3.8 ‡ (PP)	2.4±0.89 ‡ (PP)	2.1±0.8 ‡ (PP)	2.5	50	3-7.	3-7.	Y	NA
Wang et al. [5]	China	112	57	55	1		28.5±7.6 ‡ (ITT)	28.3±7.5 ‡ (ITT)	24.9±8.4 ‡ (ITT)	25.3±7.9 ‡ (ITT)	2.4±0.7 ‡ (ITT)	2.3±0.6‡ (ITT)	2.5	50	5-9.	5-9.	Y	NA
Zafar et al. [46]	Pakistan	360	180	180	1		26.61±4.81 ‡ (PP)	27.89±4.24 ‡ (PP)	NA	NA	4.11±3.5‡ (PP)	4.7±3.4 ‡ (PP)	2.5	50	2-6.	2-6.	NA	NA
Studies includ	ed only in the	systematic revi	ew															
Al-Shaikh et al. [47]	Iraq	85	40	45	LE group:	CC group:		18-40 §§ (LE + CC group) (PP)	NA	NA	NA	NA	5	100	25.	25.	NA	NA
Amer et al. [48]	The United Kingdom	149	75	74	LE group:	CC group:	28.3± 4.4 ‡ (ITT)	28.1±4.2* (ITT)	27.5 (23.4 -32.2) § (ITT)	27.7 (23.0-31.0) § (ITT)	1.5 (1.0-2.0) § (ITT)	1.5 (1.0-2.0) § (ITT)	2,5->5	50->100	2/4-6/8	2/4-6/8	NA	NA
Bansal et al.	India	80	41	39		CC group:	27.0 ± 3.56 ‡	26.0 ± 3.97 ‡ (ITT)	23.90 ± 3.57 ‡ (ITT)	23.10 ± 3.64 ‡ (ITT)	3.9 ± 2.3 ‡ (ITT)	3.4 ± 2.3 ‡ (ITT)	2.5->7.5	50->150	2-6.	2-6.	Y	NA
Baruah et al. [57]	India	50	25	25	LE group:	CC group:	29.7±0.5 ‡ (PP)	30.2±0.5 ‡ (PP)	23.6±0.04 ‡ (PP)	24.52±0.02 * (PP)	2.7±0.2 ‡ (PP)	2.9±0.5 ‡ (PP)	2.5->5	50->100	5-9.	5-9.	Y	NA

					58													
					LE													
Bayar et al. [49]	Turkey				group:	CC group:												
		74	38	36	99	95	32.2 ±3.9 ‡ (PP)	30.6± 4 ‡ (PP)	NA	NA	5 (1-10) § (PP)	3 (1-11) § (PP)	2.5	100	3-7.	3-7.	Y	NA
Legro et al.	The United				LE group:	CC group:												
[50]	States						28.9±4.5 ‡	28.8±4.0 ‡			40.9±38.0 ‡							
		750	374	376	5	5	(PP)	(PP)	35.2±9.5 ‡ (PP)	35.1±9.0 ‡ (PP)	(PP)	42.5±37.6 ‡ (PP)	2.5->7.5	50->150	3-7.	3-7.	NA	NA
Domest al					LE													
Ray et al. [54]	India				group:	CC group:												
		147	69	78	132	156	28 (19-35) § (PP)	29 (20-35) § (PP)	28.8 (23.2-34.6) § (PP)	28.5 (24.2-33.6) § (PP)	2.2 ‡‡ (PP)	2.4 ‡‡ (PP)	2.5	100	3-7.	3-7.	Y	NA
					LE													
Roy et al [51]	India				group:	CC group:			25.8	25.4±1.56	_	5.8						
		204	0.0	106	204	210	26.1±1.8 ‡		±2.1 ‡ (PP)	_	6.4±3.8 ‡		25.5	50 > 100	2.7	2.7	V	NA
		204	98		294	318	(PP)	(PP)	±2.1 ‡ (PP)	‡ (PP) -	(PP)	±3.1 ‡ (PP)	2.5->5	50->100	3-7.	37.	Y	NA
Sakar et al.	Turkey				LE group:	CC group:												
[52]	Turkey				group.	CC group.		24.61.4.45			2 (1 12) 8							
		323	175	148	1 or 6	1 or 6	25.9±4 ‡ (PP)	24.6±4.4‡ (PP)	25.4±3.2 ‡ (PP)	24.8±2.9 ‡ (PP)	2 (1-12) § (PP)	2 (1-11) § (PP)	5	100	2-5.	2-5.	NA	NA
					LE													
Sharief et al. [53]	Iraq				group:	CC group:												
		75	35	40	6	6	26.1±1.3 ‡ (PP)	25.3±2.1 ‡ (PP)	28.1±1.91 ‡ (PP)	27.8±1.7 ‡ (PP)	2.4±0.6 ‡ (PP)	2.3±0.4 ‡ (PP)	2,5-5	100-200	3-7.	3-7.	Y	NA

‡ parameters represented as mean with standard deviation

‡‡ parameters represented as mean

§ parameters represented as median (min-max)

§§ parameters represented as min-max

\* number of patients

\*\* % of patients

ITT: data were analyzed intention-to-treat

PP: data were analyzed per-protocol

N°: number

LE: letrozole

CC: clomiphene citrate

BMI: body mass index

Y: yes; NA: no data available; N: no

^: the studied patient population is the same as Al-Obaidi et al. 2019 [15], with patients included in the article; therefore, we only included these results once in our meta-analysis

Results of the quantitative analysis 250 On the basis of the results of 11 studies including 1,651 patients, ET was significantly higher 251 in LE group /Mean difference (MD)=1.70, CI: 0.55-2.86; I<sup>2</sup>=97%, p=0.008/ compared to CC 252 group (Fig 2A). The subset analysis conducted on only ovulating patients showed thicker 253 endometrium in LE group; however, this difference did not reach the level of statistical 254 significance /MD=2.2, CI: -0.38-4.78; I<sup>2</sup>=97%, p=0.077/ (**S1 Fig**). 255 Fig 2A) Forest plot for endometrial thickness (ET) - all patients. Legend: LE-letrozole; 256 CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; 257 258 CI-confidence interval; p-p-value. S1 Fig. Forest plot for endometrial thickness (ET) - ovulating patients only. Legend: LE-259 letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard 260 261 deviation; CI-confidence interval; p-p-value. On the basis of the results of 9 studies including 1,510 patients, **odds of ovulation** and based 262 on the results of 11 studies including 1410 patients, **odds of pregnancy** were significantly 263 higher in LE patients /ovulation rate: odds ratio (OR)=1.80, CI: 1.21-2.69; I<sup>2</sup>=51%, p=0.010 264 (Fig 2B); pregnancy rate: OR=1.96, CI: 1.37-2.81; I<sup>2</sup>=32%, p=0.002 (Fig 2C)/ compared to 265 CC patients. In patients who ovulated as a result of the drug therapy used, odds of pregnancy 266 were also higher in LE group, but this difference did not reach the level of statistical 267 significance /OR=1.65, CI: 0.40-6.76; I<sup>2</sup>=56%, p=0.337/ (**Fig S5**). 268 Fig 2B) Forest plot for ovulation rate. Legend: LE-letrozole; CC-clomiphene citrate; N-269 number of patients; OR-odds ratio; CI-confidence interval; p-p-value. 270

- Fig 2C) Forest plot for pregnancy rate all patients. Legend: LE-letrozole: CC-271
- 272 clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

S5 Fig. Forest plot for pregnancy rate - ovulating patients only. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-pvalue. On the basis of the results of 3 studies including 460 patients, **RI of subendometrial arteries** was significantly lower in LE patients /MD=-0.15, CI: -0.27- -0.04; I<sup>2</sup>=92%, p=0.030/ compared to CC patients (Fig 3A). PI of subendometrial arteries was also lower in the LE group /MD=-0.17, CI: -0.81-0.47; I<sup>2</sup>=95%, p=0.372/, but this difference did not reach the level of statistical significance (Fig 3B). Fig 3A) Forest plot for subendomendometrial circulation - resistance index (RI) of subendometrial arteries. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; CI-confidence interval; p-p-value. Fig 3B) Forest plot for subendomendometrial circulation - pulsatility index (PI) of **subendometrial arteries.** Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; CI-confidence interval; p-p-value. On the basis of the results of 8 studies including 253 patients, **odds of multiple pregnancies** were higher in CC patients /multiple pregnancies: OR=0.41, CI: 0.12-1.35; I<sup>2</sup>=0%, p=0.119/ compared to LE patients (S6 Fig), but this difference did not reach the level of statistical significance. S6 Fig. Forest plot for multiple pregnancy rate. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value. On the basis of the results of 4 studies including 160 patients, there was no difference in the miscarriage rate /OR=0.62, CI: 0.19-1.98; I<sup>2</sup>=0%, p=0.278/ (S7 Fig). S7 Fig. Forest plot for miscarriage rate. Legend: LE-letrozole; CC-clomiphene citrate; Nnumber of patients; OR-odds ratio; CI-confidence interval; p-p-value.

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

There was no significant difference between groups in the **number** of **follicles** /MD=-0.40, CI: -0.84-0.03; I<sup>2</sup>=91%, p=0.066/ based on the results of 9 studies including 1264 patients (**S2 Fig**) and the **diameter** of **follicles** /MD=0.58, CI: -0.17-1.32;  $I^2=45\%$ , p=0.092/ based on the results of 4 studies including 660 patients (S4 Fig) although more but smaller follicles were seen in CC group. In the subset analysis of the number of follicles conducted in patients who only ovulated, there was also no significant difference between the two groups /MD=-0.80 CI: -2.48-0.89;  $I^2 = 80\%$ ; p = 0.179/ (S3 Fig). S2 Fig. Forest plot for number of dominant follicles – all patients. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation. CI-confidence interval; p-p-value. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation. S4 Fig. Forest plot for diameter of dominant follicles. Legend: LE-letrozole; CCclomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation. S3 Fig. Forest plot for number of dominant follicles - ovulating patients only. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SDstandard deviation. On the basis of the results of 3 studies including 563 patients, the **odds** were higher **for** monofollicular development and lower for multifollicular development in LE patients /monofollicular development: OR=1.99, CI: 0.62-6.34; I<sup>2</sup>=51%, p=0.126 (**S8 Fig**); in the case of multifollicular development: OR=0.50, CI: 0.16-1.61; I<sup>2</sup>=51%, p=0.126 (**S9 Fig**)/ compared to CC patients, but this difference did not reach the level of statistical significance. S8 Fig. Forest plot for monofollicular development rate. Legend: LE-letrozole: CCclomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

S9 Fig. Forest plot for multifollicular development rate. Legend: LE-letrozole; CC-clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

Results of the qualitative analysis

Results and main conclusions of the studies only comprised in the systematic review are detailed in Table 2.

Table 2. Main conclusions of the studies only included in the systematic review

Author (year)	Endometria I thickness	Endometria l volume	Multilayered endometrial pattern and/or echogenicity	N° of dominant follicles	Diameter of dominan t follicles	Monofollicula r development cycles	Multifollicula r development cycles	Ovulation rate	Pregnancy rate	N° of multiple pregnancie s	N° of miscarriage s	Live birth rate	Prevalenc e of ectopic pregnanc y	N° of fetal anomalie s	endometrial VI, FI VFI or detection rate of endometrial- subendometria l blood flow	RI and PI of subendometria l arteries	SV/DV of subendometria l arteries	RI and PI of uterine arteries	VEGF and/or integrin alpha vB3 concentratio n in uterine fluid
Al- Obaidi et al. [15]	significantly higher in LE group \$	NA	NA	#	#	NA	NA	NA	#	NA	NA	NA	NA	NA	NA	NA	significantly higher in LE group	NA	VEGF has significantly negative correlation with endometrial RI in LE group, no similar correlation was in CC group
Al- Shaikh et al. [47]	significantly higher in CC group	NA	NA	significantl y higher in LE group ¤	no significan t differenc e between LE and CC groups ¤	NA	NA	NA	no significant difference between LE and CC groups ¤	NA	one patient in LE group, 2 in CC group	NA	NA	NA	NA	NA	NA	NA	NA
Amer et al. [48]	significantly higher in CC group	NA	no significant difference between LE and CC group	NA	NA	NA	NA	no significant difference between LE and CC groups, but analyzing the data per cycle significantl y higher in LE group	significantl y higher in LE group	NA	NA	no significant difference between LE and CC groups	NA	none in LE and in CC group	NA	NA	NA	NA	NA
Bansal et al. [55]	no significant difference between LE and CC groups	NA	NA	NA	NA	significantly higher in LE group	NA	no significant difference between LE and CC groups §	significantl y higher in LE group	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Baruah et al. [57]	significantly higher in LE group	NA	NA	no significant difference between LE and CC groups	NA	NA	NA	NA	no significant difference between LE and CC groups	none in LE and in CC group	NA	NA	NA	NA	NA	significantly lower in LE group	NA	NA	NA
Bayar et al. [49]	similar between LE and CC	NA	NA	significantl y lower in LE group	NA	NA	NA	NA	no significant difference	none in LE and CC groups	one patient in LE group	no significant difference	NA	NA	NA	NA	NA	NA	NA

	groups								between LE and CC groups ¤			between LE and CC groups ¤							
Ghahiri et al. [6]	NA	NA	NA	NA	NA	NA	NA	NA	#	#	#	NA	no significant difference between LE and CC groups	NA	NA	NA	NA	NA	NA
Hussein et al. [42]	significantly higher in LE group \$\$	NA	multilayered endometrial pattern and hypoechogenic endometrium significantly more occurred in LE group (hypoechogeni c endometrium was highly significant associated with pregnancy in both groups)	##	##	NA	NA	NA	##	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Legro et al. [50]	significantly higher in CC group	NA	NA	NA	NA	NA	NA	significantl y higher in LE group	significantl y higher in LE group	no significant difference between two groups	no significant difference between LE and CC groups	significantl y higher in LE group	NA	four patients in LE group and 1 in CC group	NA	NA	NA	NA	NA
Ray et al. [54]	significantly higher in LE group	NA	NA	no significant difference between LE and CC groups ¤	no significan t differenc e between LE and CC groups	majority of induced cycles in LE and CC group	NA	NA	no significant difference between LE and CC groups	NA	one patient in CC group	NA	NA	none in LE and in CC group	NA	NA	NA	NA	NA
Roy et al [51]	significantly higher in LE group	NA	NA	no significant difference between LE and CC groups	NA	NA	NA	similar between LE and CC groups	no significant difference between LE and CC groups ¤	not in LE group, 3 patients in CC group	no significant difference between LE and CC groups	significantl y higher in LE group	NA	NA	NA	NA	NA	NA	NA
Sakar et al. [52]	significantly higher in LE group	NA	NA	similar between LE and CC groups	NA	NA	NA	significantl y higher in LE group ¤	significantl y higher in LE group	not in LE and in CC group	no significant difference between LE and CC groups	significantl y higher in LE group	NA	one patient in LE group and 1 in CC group	NA	NA	NA	NA	NA
Sharief et al. [53]	significantly higher in LE group	NA	NA	significantl y lower in LE group	NA	NA	NA	significantl y higher in LE group	no significant difference between	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

									LE and CC groups										
Wang et al. [1]	#	significantly higher in LE group	multilayered endometrial pattern occurred in LE group significantly more frequently	#	#	NA	NA	#	S	NA	NA	NA	NA	NA	endometrial VI-FI-and VFI was significantly higher in LE group	#	NA	no significan t differenc e between LE and CC groups	NA
Wang et al. [5]	#	significantly higher in LE group	NA	#	#	NA	NA	#	#	NA	NA	NA	NA	NA	endometrial VI-FI-and VFI were significantly higher in LE group	NA	NA	no significan t differenc e between LE and CC groups	significantly higher in LE group
Dehbash i et al. [56]	#	NA	NA	#	NA	NA	NA	#	#	#	#	no significant difference between LE and CC groups	NA	none in LE group, 1 in CC group	NA	NA	NA	NA	NA
Selim et al. [19]	#	NA	NA	#	NA	NA	NA	#	#	#	NA	NA	NA	NA	rate of endometrial- subendometrial blood flow was significantly lower in LE group	#	NA	NA	NA

N°: number

LE: letrozole

CC: clomiphene citrate

a: data are given per cycle

§: cumulative ovulation rate

#: data are involved in quantitative analysis in meta-analysis (see in results)

##: data are involved in quantitative analysis in meta-analysis (the studied patient population is the same as in the article by Al-Obaidi et al. 2019 [15], therefore we only included these results once in our meta-analysis; see the results of the Al-Obaidi et al. [15])

\$: the given results could not be used for our quantitative analysis, so we did not include them in our meta-analysis

\$\$: the studied patient population is the same as in the article by Al-Obaidi et al. 2019 [15], but the given results could not be used for our quantitative analysis, so we did not include them in our meta-analysis and we only included these results once in our qualitative analysis in systematic review

## **Quality assessment**

The results of the quality assessment are listed in the Summary of Findings Table (S1 Table

346 in the Supplement).

344

345

347

349

350

351

352

353

354

#### **Publication bias**

No evidence of publication bias was detected (S10-14 Figs in the Supplement). 348

The funnel plots do not indicate publication bias and the result of Egger's test was not

significant, which means publication bias could not be detected. Significant heterogeneity was

observed for ET, number of dominant follicles and diameter of dominant follicles, RI of

subendometrial artery, and PI of subendometrial artery. Other outcome measures showed low

or moderate heterogeneity.

#### Risk of bias assessment

The results of the risk of bias assessment are shown **S15-70 Figs** in the Supplement. 355

## **Discussion**

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

PCOS and infertility caused by PCOS are huge problems worldwide, the treatment of which has not been solved. Intensive research is underway to find the right drug for ovulation induction; however, there is no comprehensive summary of the results of the studies so far. In our study, we summarized the results of the available publications and identified several positive properties of LE as an ovulation induction drug compared to the currently widely used CC. Thicker endometrium is associated with better embryo implantation [20]. ET in our metaanalysis was significantly thicker in LE group compared to CC group. When we compared our result with previous meta-analyses by He et al. found that the data of the articles included in the analysis could not be pooled due to significant heterogeneity [58]. However, Gadalla et al. stated that the endometrium was significantly thinner in CC group [11]. Akinoso-Imran et al. found similar results after letrozole treatment [59]. Of the RCTs included in our qualitative analysis (**Table 2**), six found significantly thicker endometrium in LE group [15, 42, 51-54, 57], three found significantly thicker endometrium in CC group [47, 48, 50], and two found no significant difference between the two groups [49, 55]. In other studies, the endometrial volume was significantly higher [1, 5] significantly more multilayered endometrial pattern [1, 42] and hypoechogenic endometrium occurred [42] in LE group. In contrast, one found no significant difference between the two groups in terms of endometrial pattern and echogenicity [48]. Patients taking CC appear to have more but smaller follicles, which may reduce the chance of appropriate maturation, follicle rupture and increase the risk of hyperstimulation and the odds of multiple pregnancies [60]. We found that the number of dominant follicles was higher in patients taking CC, although the definition of dominant follicle differed in the articles (from 12 mm< to 18 mm =/<). The diameters of follicles did not differ significantly; however, the

follicles in LE group were larger. When we compared our results with previous metaanalyses, we found that He et al. observed significantly fewer mature follicles per cycle in patients taking letrozole [58]. In another study, the standardized mean difference revealed no statistically significant difference between patients treated with LE or CC, but there were also fewer mature follicles in letrozole group [59]. Of the RCTs included in our qualitative analysis (**Table 2**), one found significantly higher numbers of dominant follicles in LE group [47], two found significantly lower numbers in LE group [48, 49], and four found no significant difference between the two groups [51, 52, 54, 57]. As for the diameter of the dominant follicles, two found no significant difference between the two groups [47, 54]. Ovulation is essential for fertilization. We have previously presented that patients in LE group had significantly higher odds of ovulation than in CC group. In comparison of our result with previous meta-analyses, He et al. [58], Tsiami et al. [61] and Zhuo et al. [62] reported the same result. Wang et al. pointed out that the ovulation rate was significantly better when patients were taking LE instead of CC [63]. In contrast, Roque et al. [64] and Gadalla et al. [11] reported that the odds of ovulation were similar in letrozole group and in CC group. Akinoso-Imran et al. also found that letrozole treatment caused a significantly higher ovulation rate compared to CC [59]. Shifu Hu et al. had similar results [65]. Of the RCTs included in our qualitative analysis (**Table 2**), three found significantly higher ovulation rates in LE group [50, 52, 53], two found no significant difference between the two groups [51, 55]. One found no significant difference in ovulation rate, but when analyzing the data per cycle found, it reported significantly higher in LE group [48]. Another one found the monofollicular development significantly higher [55] in LE group and one found the same majority of cycles included in both groups [54]. It would be good if more women with PCOS increased their chances of getting pregnant. We found that the odds of pregnancy were significantly higher in patients treated with letrozole

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

than in CC group. In comparison of our result with previous meta-analyses, four were found to have significantly higher pregnancy rates [59, 62-64] and three were reported to have significantly higher odds of live birth [62-64] after letrozole treatment. Gadalla et al. [11] and Hu et al. [65] described similar differences between the two groups. In contrast, He et al. found no significant difference in the odds of pregnancy between the two groups [58]. Of the RCTs included in our qualitative analysis (Table 2), four found significantly higher pregnancy rates in LE group [48, 50, 52, 55], but the other six found no significant difference between the two groups [47, 49, 51, 53, 54, 57]. Three found significantly higher live birth rates in LE group [50-52], and three found no significant difference between the two groups [48, 49, 56]. Multiple pregnancy increases the odds of almost every potential complication of singleton pregnancy (e.g. preterm birth, fetal growth restriction, etc.) [66]. In our research, the odds of single pregnancies were higher amongst letrozole patients, and more multiple pregnancies occurred amongst CC patients, although this difference did not reach the level of statistical significance. Four previous meta-analyses came to a similar non-significant conclusion [58, 59, 63, 65]. In three of the RCTs included in our qualitative analysis (**Table 2**), no multiple pregnancies occurred in either group [49, 52, 57]. One found no multiple pregnancy in LE group, and three in CC group [51]. One found no significant difference between the two groups [50]. The aim should not only be to achieve pregnancy, but also to carry as many pregnancies to term as possible among women with PCOS. In our study, the odds of miscarriage were higher in CC group, but this difference did not reach the level of statistical significance. Our results are consistent with previous meta-analyses in the literature. [58, 59, 63-65]. Of the RCTs included in our qualitative analysis (Table 2), three found no significant difference in the number of miscarriages between the two groups [50-52], other studies found no difference or

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

one or two in groups [47, 49, 54]. In the prevalence of ectopic pregnancy, one found no significant difference between the two groups [57]. Fetal anomalies were not found in either group in two RCTs [48, 54], Legro et al. found four in LE group, one in CC group [50], one found one in LE group, one in CC group [52], one other found no cases in LE group, one in CC group [56]. The RI of subendometrial arteries was significantly lower in LE group than in CC group. The PI of subendometrial arteries was also lower in patients treated with letrozole, but this result was not statistically significant. With lower RI and PI, intrauterine blood supply is better, and there may be a greater chance of improved intrauterine embryonic development. Wang et al. in their RCT found no difference in PI values between the LE or the CC group after Diane-35 and metformin pretreatment (therefore, we did not include these articles in our meta-analysis); however, the RI of subendometrial arteries was also significantly lower in LE group [67]. One RCT examined PI and RI of spiral arteries for six months; RI and PI were significantly lower in letrozole group [68]. Of the RCTs included in our qualitative analysis (**Table 2**), one also found significantly lower RI and PI of subendometrial arteries in LE group (they used an increasing drug dose and examined several cycles, so they were not included in our metaanalysis) [57]. Two found significantly higher endometrial vascularization index, flow index and vascularization flow index in LE group, and no significant difference in RI and PI of uterine arteries between the two groups [1, 5]. One found that the detection rate of endometrial-subendometrial blood flow was significantly lower in LE group [19]. One found significantly higher systolic velocity/diastolic velocity of subendometrial arteries and a significantly negative correlation in vascular endothelial growth factor concentration with endometrial RI in LE group, although there was no similar correlation in CC group [15]. One found significantly higher vascular endothelial growth factor and integrin alpha vß3 concentrations in uterine fluid in LE group [5].

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

We obtained results similar to the majority of previous meta-analyses, with the difference that we also highlighted that a better effect can be achieved with the use of LE compared to CC, even in one cycle. We are the first to use a meta-analysis to confirm the result that the use of LE might be beneficial for subendometrial ciculation compared to CC, which may explain the significant increase in the pregnancy rate among women with PCOS treated with letrozole. The previously mentioned changes in the subendometrial circulation are very early changes after one cycle, which may explain the differences in significance between RI and PI values. With longer-term use, the differences might also become significant for the PI values. Strengths and limitations We used only randomized trials for our meta-analysis. The unique quality of this metaanalysis is that we separated and systematized the results of previous studies on women with PCOS treated with LE or CC according to whether the patients were followed for one or more cycles and whether they received a fixed or increasing drug dose used to induce ovulation. In this way, in contrast to previous meta-analyses, we have reduced the possibility of distortion that could be resulted by a quantitative analysis after combining the above research results. For a quantitative analysis, we found sufficient data only from research studies that used fix doses of the drugs over one cycle. Only a moderate number of studies could be included because the results of patients examined over one cycle could not be combined with the total results of patients examined over several cycles, nor with the results of patients whose medication dose was increased during the examination, if necessary, in order to provide accurate data. Furthermore, not all eligible studies used the same drug dose of LE or CC. Another limitation is the presence of moderate and high risk of bias in some of the domains.

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

### Implications for practice and research

The significance of immediate application of research findings in clinical practice cannot be underestimated [69]. On the basis of the results of research findings we have analyzed, we can claim that LE should be considered for introduction into clinical practice worldwide among women with PCOS as a first-line oral ovulation induction drug. On the basis of our very encouraging results, we suggest further prospective data collection on subendometrial arterial circulation in women with PCOS during their treatment with letrozole for OI.

In the future, in order to provide more accurate data, it would be important to conduct as many research studies with the same number of cycles as possible and to accurately record the effects observed with each drug dose, to the extent that the dose of LE and CC is increased during the study.

**Conclusion** Our results show that letrozole is an effective therapeutic option for the treatment OI in patients with PCOS. Comparing LE with CC, which is the gold standard drug for OI, we can claim that the administration of LE resulted higher ovulation rates, thicker endometrium, lower RI of subendometrial arteries, and higher pregnancy rates. Lower RI in the subendometrial arteries can not only increase the chance of embryo implantation but also improve embryo development. For the above reasons, we recommend that LE should be considered as a first-line drug for ovulation induction.

# Acknowledgments

None. 

### References

- 534 Wang L, Wen X, Lv S, Zhao J, Yang T, Yang X. Comparison of endometrial
- receptivity of clomiphene citrate versus letrozole in women with polycystic ovary syndrome: 535
- a randomized controlled study. Gynecol Endocrinol. 2019;35(10):862-5. doi: 536
- 10.1080/09513590.2019.1612358. PubMed PMID: rayyan-906439176. 537
- Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus 538
- on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam 539
- ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 540
- 2012;97(1):28-38.e25. Epub 20111206. doi: 10.1016/j.fertnstert.2011.09.024. PubMed PMID: 541
- 22153789. 542

- 543 Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with
- anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986;293(6543):355-9. doi: 544
- 10.1136/bmj.293.6543.355. PubMed PMID: 3089520; PubMed Central PMCID: 545
- 546 PMC1341046.
- Elsedeek MS-E-A. Elmaghraby HAH. Predictors and characteristics of letrozole 547
- induced ovulation in comparison with clomiphene induced ovulation in anovulatory PCOS 548
- women. Middle East Fertility Society Journal. 2011;16(2):125-30. doi: 549
- 550 10.1016/j.mefs.2010.11.004.
- Wang L, Lv S, Li F, Bai E, Yang X. Letrozole Versus Clomiphene Citrate and Natural 551
- Cycle: Endometrial Receptivity During Implantation Window in Women With Polycystic 552
- Ovary Syndrome. 2021(1664-2392 (Print)). 553
- Ghahiri A, Mogharehabed N, Mamourian M. Letrozole as the first-line treatment of 554
- infertile women with poly cystic ovarian syndrome (PCOS) compared with clomiphene 555
- citrate: A clinical trial. Adv Biomed Res. 2016;5:6. Epub 20160129. doi: 10.4103/2277-556
- 9175.175237. PubMed PMID: 26962508; PubMed Central PMCID: PMC4770610. 557
- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence 558
- and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol 559
- Metab. 2004;89(6):2745-9. doi: 10.1210/jc.2003-032046. PubMed PMID: 15181052. 560
- Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. 561
- 2006(0021-972X (Print)). 562
- Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 563
- 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary 564
- 565 syndrome. 2004(0015-0282 (Print)).
- Naseri S. The role of Clomiphene citrate in the treatment of infertility. J Mazandaran 566
- Univer Med Sci. 2004:14:106-23. 567
- Gadalla MA-O, Huang S, Wang R, Norman RJ, Abdullah SA, El Saman AM, et al. 568
- 569 Effect of clomiphene citrate on endometrial thickness, ovulation, pregnancy and live birth in
- anovulatory women: systematic review and meta-analysis. Ultrasound in Obstetrics & 570
- Gynecogy. 2018(1469-0705):51(1):64-76. doi: 10.1002/uog.18933. 571
- Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in 572
- patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305-9. 573
- doi: 10.1016/s0015-0282(00)01705-2. PubMed PMID: 11172831. 574
- Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G. The role 575 13.
- of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson 576
- 577 Cancer Center evidence-based approach. Cancer. 2004;101(7):1482-9. doi:
- 10.1002/cncr.20522. PubMed PMID: 15378476. 578
- Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and 579
- inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J 580
- Natl Cancer Inst. 2006;98(18):1285-91. doi: 10.1093/jnci/djj357. PubMed PMID: 16985247. 581

- 15. Al-Obaidi MT, Ali ZH, Saadi Wi AL, Wasiti Ear AL, Al-Aubaidy H. Impact of 582
- 583 letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic
- ovarian syndrome. Journal of clinical pharmacy and therapeutics. 2019. PubMed PMID: 584
- rayyan-906438017. 585
- Najafi PZ, Noghabi SP, Afzali N, Mohammadzadeh S. Comparing the effect of 586
- clomiphene citrate and letrozole on ovulation induction in infertile women with polycystic 587
- ovary syndrome. J Pak Med Assoc. 2020;70(2):268-71. doi: 10.5455/jpma.267607. PubMed 588
- PMID: rayvan-906438739. 589
- 17. Gibbs RS, Haney AF. Danforth Obstetrics & Gynecology. China: Lippincott Williams 590
- & Wilkins; 2010. 591
- Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a 592
- review of their clinical benefits in the second-line hormonal treatment of advanced breast 593
- 594 cancer. Ann Oncol. 1999;10(4):377-84. doi: 10.1023/a:1008368300827. PubMed PMID:
- 595 10370778.
- Selim MF, Borg TF. Letrozole and clomiphene citrate effect on endometrial and 596 19.
- 597 subendometrial vascularity in treating infertility in women with polycystic ovary syndrome.
- Journal of Gynecologic Surgery. 2012;28(6):405-10. doi: 10.1089/gyn.2012.0033. PubMed 598
- 599 PMID: rayvan-906438965.
- 600 20. Khan MS, Shaikh A, Ratnani R. Ultrasonography and Doppler Study to Predict
- Uterine Receptivity in Infertile Patients Undergoing Embryo Transfer. J Obstet Gynaecol 601
- India. 2016;66(Suppl 1):377-82. Epub 20150908. doi: 10.1007/s13224-015-0742-5. PubMed 602
- 603 PMID: 27651633; PubMed Central PMCID: PMC5016392.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. 604
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 605
- 606 2021;372:n71. Epub 20210329. doi: 10.1136/bmj.n71. PubMed PMID: 33782057; PubMed
- Central PMCID: PMC8005924. 607
- Chandler J, Hopewell S. Cochrane methods--twenty years experience in developing 608 22.
- systematic review methods. Syst Rev. 2013;2:76. Epub 20130920. doi: 10.1186/2046-4053-2-609
- 76. PubMed PMID: 24050381; PubMed Central PMCID: PMC3849105. 610
- 611 23. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges, and
- Guiding Treatment. J Clin Endocrinol Metab. 2021;106(3):e1071-e83. doi: 612
- 613 10.1210/clinem/dgaa839. PubMed PMID: 33211867.
- 24. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 614
- 14: Completing 'summary of findings' tables and grading the certainty of the evidence. In 615
- 616 Cochrane Handbook for Systematic Reviews of Interventions. Cochrane: 2022 2022.
- R Core T. R: A Language and Environment for Statistical Computing Vienna, Austria: 617
- R Foundation for Statistical Computing; 2023. Available from: https://www.R-project.org/. 618
- 619 26. Schwarzer G. Meta: General Package for Meta-Analysis 2023. Available from:
- https://github.com/guido-s/meta/ 620
- https://link.springer.com/book/10.1007/978-3-319-21416-0. 621
- Harrer M, Cuijpers P, Ebert D. Doing Meta-Analysis in R. 2019. doi: 622 27.
- 10.5281/zenodo.2551803. 623
- Mantel N, Haenszel W. Statistical Aspects of the Analysis of Data From Retrospective 624
- Studies of Disease. Journal of the National Cancer Institute. 1959;22(4):719–48. doi: 625
- 626 10.1093/jnci/22.4.719.
- Robins J, Greenland S, N.E. B. A general estimator for the variance of the Mantel-627
- Haenszel odds ratio. American Journal of Epidemiology. 1986:719-23. doi: 628
- 629 10.1093/oxfordjournals.aje.a114447.
- 30. Cooper HM, L.V. H, J.C. V, eds. The Handbook of Research Synthesis and Meta-630
- Analysis. 2nd ed. . New York: Russell Sage Foundation 2009. 631

- Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of 632 31.
- 633 continuity corrections in meta-analysis of sparse data. 2004;23(9):1351-75. doi:
- 10.1002/sim.1761. 634
- Paule RC, Mandel J. Consensus Values and Weighting Factors. Journal of Research of 635 32.
- the Nacional Bureau of Standards 1982:377-85. doi: 10.6028/jres.087.022. PubMed Central 636
- PMCID: PMC6768160. 637
- Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. 638 33.
- Methods to estimate the between-studyvariance and its uncertainty inmeta-analysis. Research 639
- 640 Synthesis Methods. 2015:55–79. doi: 10.1002/jrsm.1164.
- Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis with R: A 641
- Hands-On Guide. 1st ed. Boca Raton, FL; London: Chapman & Hall/CRC Press; New York: 642
- Chapman and Hall/CRC Press2021. 643
- Knapp G, Hartung J. Improved tests for a random effects meta-regression with a 644
- single covariate. Statistics in Medicine. 2003;22(17):2693-710. doi: 10.1002/sim.1482. 645
- IntHout J, J.P.A. I, Borm GF. The Hartung-Knapp-Sidik-Jonkman method forrandom 646
- 647 effects meta-analysis is straightforwardand considerably outperforms the
- standardDerSimonian-Laird method. BMC Medical Research Methodology. 2014. 648
- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics 649
- 650 in Medicine. 2002;21(11):1539-58. doi: 10.1002/sim.1186.
- 38. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by 651
- 652 a simple, graphical test. BMJ. 1997;315(7109):629-34. doi: 10.1136/bmj.315.7109.629.
- PubMed PMID: 9310563; PubMed Central PMCID: PMC2127453. 653
- Harbord RM, Ross JH, Sterne JAC. Updated Tests for Small-Study Effects in Meta-654
- Analyses. The Stata Journal: Promoting Communications on Statistics and Stata. 2009:197– 655
- 656 210. doi: 10.1177/1536867X0900900202.
- Atay V, Cam C, Muhcu M, Cam M, Karateke A, Comparison of letrozole and 657
- clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int 658
- Med Res. 2006;34(1):73-6. doi: 10.1177/147323000603400109. PubMed PMID: rayyan-659
- 906438063. 660
- Hendawy SF, Samaha HE, Elkholy MF. Letrozole versus Clomiphene Citrate for 41. 661
- Induction of Ovulation in Patients with Polycystic Ovarian Syndrome Undergoing 662
- 663 Intrauterine Insemination. Clin Med Insights Reprod Health. 2011;5:11-6. doi:
- 10.4137/cmrh.S6598. PubMed PMID: rayyan-906438426. 664
- Hussein Z, Al-Obaidi MT, Al-Saadi WI, Selman MO. Comparison of the effect of 665
- 666 clomiphene citrate and letrozole on the endometrial parameters of PCOS women. Journal of
- pharmaceutical sciences and research. 2017;9(11):2291-5. PubMed PMID: rayyan-667
- 906438467. 668
- 669 43. Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile
- PCOS women: a prospective randomized trial. Journal of human reproductive sciences. 670
- 2012;5(3):262-5. doi: 10.4103/0974-1208.106338. PubMed PMID: rayyan-906438547. 671
- 672 44. Khakwani M, Parveen R, Yousaf S, Tareen AU. Efficacy of letrozole versus
- clomiphene citrate on ovulation induction in patients with polycystic ovarian syndrome. 673
- Pakistan journal of medical sciences. 2022;38(5):1155-8. doi: 10.12669/pjms.38.5.5565. 674
- 675 PubMed PMID: rayyan-906438559.
- Mobusher I. Comparison of the Efficacy of Letrozole and Clomiphene Citrate for 676
- Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome. . 905 P J M H S 677
- 2014; VOL. 8 NO.4 678
- Zafar T, Asif F, Naurin R, Majeed T, Mahmood Z. Comparing effectiveness of 679
- letrozole versus clomiphene citrate to evaluate the ovulation induction in patients with 680

- polycystic ovarian syndrome. Pakistan journal of medical and health sciences. 681
- 2021;15(10):2685-8. doi: 10.53350/pjmhs2115102685. PubMed PMID: rayyan-906439302. 682
- 683 Al-Shaikh SFMH, Al-Mukhatar EJ, Al-Zubaidy AA, Al-Rubaie BJU, Al-Khuzaee L.
- Use of clomiphene or letrozole for treating women with polycystic ovary syndrome related 684
- subfertility in Hilla city. Middle East Fertility Society Journal. 2017;22(2):105-10. doi: 685
- 10.1016/j.mefs.2016.12.003. PubMed PMID: rayyan-906438019. 686
- Amer SA, Smith J, Mahran A, Fox P, Fakis A. Double-blind randomized controlled 687
- trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian 688
- syndrome. Hum Reprod. 2017;32(8):1631-8. doi: 10.1093/humrep/dex227. PubMed PMID: 689
- 28854590; PubMed Central PMCID: PMC5850470. 690
- Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in 691
- patients with polycystic ovary syndrome: a prospective randomized trial. Fertility and 692
- sterility. 2006;86(5):1447-51. doi: 10.1016/j.fertnstert.2006.04.026. PubMed PMID: rayyan-693
- 906438107. 694
- Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. 695
- 696 Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med.
- 2014;371(2):119-29. doi: 10.1056/NEJMoa1313517. PubMed PMID: rayyan-906438604. 697
- Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, et al. A prospective 698
- 699 randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of
- ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012;5(1):20-5. doi: 700
- 10.4103/0974-1208.97789. PubMed PMID: 22870010; PubMed Central PMCID: 701
- 702 PMC3409915.
- Sakar MN, Oglak SC. Letrozole is superior to clomiphene citrate in ovulation 703
- induction in patients with polycystic ovary syndrome. Pakistan Journal of Medical Sciences. 704
- 2020;36(7):1460-5. doi: 10.12669/pjms.36.7.3345. PubMed PMID: rayyan-906438951. 705
- Sharief M, Nafee NR. Comparison of letrazole and clomiphene citrate in women with 706
- polycystic ovaries undergoing ovarian stimulation. J Pak Med Assoc. 2015;65(11):1149-52. 707
- PubMed PMID: 26564281. 708
- Ray PB, Ray A, Chakraborti PS. Comparison of efficacy of letrozole and clomiphene 709
- citrate in ovulation induction in Indian women with polycystic ovarian syndrome. 2012(1432-710
- 711 0711 (Electronic)).
- 712 Bansal S, Goyal M, Sharma C, Shekhar S. Letrozole versus clomiphene citrate for
- ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized 713
- controlled trial. International Journal of Gynaecology and Obstetrics: the official organ of the 714
- 715 International Federation of Gynaecology and Obstetrics. 2020;152(3):345-50. doi:
- 10.1002/ijgo.13375. 716
- Dehbashi, S., Dehbashi, Sa., Kazerooni, T., Robati, M., Alborzi, S., Ebrahim, M., 717
- 718 Parsanezhad, Shadman, P.A. Comparison of the Effects of Letrozole and Clomiphene Citrate
- on Ovulation and Pregnancy Rate in Patients with Polycystic Ovary Syndrome. Iranian 719
- 720 Journal of Medical Sciences. 2009;34 No 1.
- Baruah J, Roy KK, Rahman SM, Kumar S, Sharma JB, Karmakar D. Endometrial 721 57.
- effects of letrozole and clomiphene citrate in women with polycystic ovary syndrome using 722
- spiral artery Doppler. Arch Gynecol Obstet. 2009;279(3):311-4. doi: 10.1007/s00404-008-723
- 724 0714-4. PubMed PMID: rayyan-906438101.
- He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic 725
- ovary syndrome. Reprod Biomed Online. 2011;23(1):91-6. Epub 20110403. doi: 726
- 10.1016/j.rbmo.2011.03.024. PubMed PMID: 21550852. 727
- Akinoso-Imran AQ, Adetunji, H. Systematic review and meta-analysis of letrozole 728
- and clomiphene citrate in polycystic ovary syndrome. Middle East Fertility Society Journal. 729
- 2018. doi: 10.1016/J.MEFS.2018.03.008. 730

- 60. Mbi Feh MK, Wadhwa, R. Clomiphene. IslandUpdated Jun 27, 2022. 731
- 732 61. Tsiami AP, Goulis DG, Sotiriadis AI, Kolibianakis EM. Higher ovulation rate with
- 733 letrozole as compared with clomiphene citrate in infertile women with polycystic ovary
- syndrome: a systematic review and meta-analysis. Hormones (Athens). 2021;20(3):449-61. 734
- 735 Epub 20210525. doi: 10.1007/s42000-021-00289-z. PubMed PMID: 34033068.
- Liu Z, Geng Y, Huang Y, Hu R, Li F, Song Y, et al. Letrozole Compared With 736
- Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-737
- analysis. Obstet Gynecol. 2023;141(3):523-34. Epub 20230202. doi: 738
- 739 10.1097/aog.00000000000005070. PubMed PMID: 36735392.
- Wang R, Li W, Bordewijk EM, Legro RS, Zhang H, Wu X, et al. First-line ovulation 740
- induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum 741
- 742 Reprod Update. 2019;25(6):717-32. doi: 10.1093/humupd/dmz029. PubMed PMID:
- 743 31647106.
- Roque M, Tostes AC, Valle M, Sampaio M, Geber S. Letrozole versus clomiphene 744 64.
- citrate in polycystic ovary syndrome: systematic review and meta-analysis. Gynecol 745
- 746 Endocrinol. 2015;31(12):917-21. Epub 20151019. doi: 10.3109/09513590.2015.1096337.
- 747 PubMed PMID: 26479460.
- Hu S, Yu O, Wang Y, Wang M, Xia W, Zhu C. Letrozole versus clomiphene citrate in 748
- 749 polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch Gynecol
- Obstet. 2018;297(5):1081-8. Epub 20180201. doi: 10.1007/s00404-018-4688-6. PubMed 750
- 751 PMID: 29392438.
- 752 66. Chasen ST. Twin pregnancy: Overview Updated May 22, 2023. Available from:
- https://www.uptodate.com/contents/twin-pregnancy-overview#. 753
- Wang L, Lü SL, Mao WJ, Bai E. Effects of clomiphene citrate and letrozole on uterine 754
- 755 artery and subendometrial blood flow in patients with polycystic ovarian syndrome. Journal
- of Xi'an Jiaotong University (Medical Sciences). 2017;38(5):734-9. doi: 756
- 757 10.7652/jdyxb201705023. PubMed PMID: rayyan-906439172.
- Sharif JH. The Induction of Ovulation in Women with Polycystic Ovarian Syndrome 758
- 759 Via: Letrozole vs Clomiphene Citrate. Journal of Pharmaceutical Negative Results.
- 2022;13(1). 760

765

- Hegyi P, Petersen OH, Holgate S, Erőss B, Garami A, Szakács Z, et al. Academia 761
- 762 Europaea Position Paper on Translational Medicine: The Cycle Model for Translating
- Scientific Results into Community Benefits. J Clin Med. 2020;9(5). Epub 20200519. doi: 763
- 764 10.3390/jcm9051532. PubMed PMID: 32438747; PubMed Central PMCID: PMC7290380.

## **Supporting Information**

- S1 Table. Summary of Findings Table. Legend: CI: confidence interval, MD: mean 769
- difference, OR: odds ratio 770

- S2 Table. PRISMA 2020 Checklist. Legend: -771
- S1 Fig. Forest plot for endometrial thickness (ET) ovulating patients only. Legend: LE-772
- letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard 773
- 774 deviation; CI-confidence interval; p-p-value.
- 775 S2 Fig. Forest plot for number of dominant follicles – all patients. Legend: LE-letrozole;
- CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; 776
- CI-confidence interval; p-p-value. 777
- S3 Fig. Forest plot for number of dominant follicles ovulating patients only. Legend: 778
- 779 LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-
- standard deviation; CI-confidence interval; p-p-value. 780
- S4 Fig. Forest plot for diameter of dominant follicles. Legend: LE-letrozole; CC-781
- clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; CI-782
- confidence interval; p-p-value. 783
- S5 Fig. Forest plot for pregnancy rate ovulating patients only. Legend: LE-letrozole; 784
- CC-clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-785
- 786 value.
- S6 Fig. Forest plot for multiple pregnancy rate. Legend: LE-letrozole; CC-clomiphene 787
- citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value. 788
- 789 S7 Fig. Forest plot for miscarriage rate. Legend: LE-letrozole; CC-clomiphene citrate; N-
- 790 number of patients; OR-odds ratio; CI-confidence interval; p-p-value.

S8 Fig: Forest plot for monofollicular development rate. Legend: LE-letrozole: CC-791 792 clomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value. 793 S9 Fig: Forest plot for multifollicular development rate. Legend: LE-letrozole; CCclomiphene citrate; N-number of patients; OR-odds ratio; CI-confidence interval; p-p-value. 794 S10 Fig. Funnel plot for endometrial thickness (ET) – all patients. Legend: -795 S11 Fig. Funnel plot for ovulation rate. Legend: -796 797 S12 Fig. Funnel plot for pregnancy rate – all patients. Legend: -S13 Fig. Funnel plot for resistance index (RI) of subendometrial arteries. Legend: -798 S14 Fig. Funnel plot for pulsatility index (PI) of subendometrial arteries. Legend: -799 800 S15 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing endometrial thickness (ET) [1, 4, 5, 16, 19, 41, 43-46, 56] using the revised tool for 801 802 assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk 803 S16 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing 804 endometrial thickness (ET) [1, 4, 5, 16, 19, 41, 43-46, 56] broken down to tools, shown in 805 806 percentage. 807 S17 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing 808 number of dominant follicles [1, 4, 5, 15, 16, 19, 40, 41, 56] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -809 : high risk 810 S18 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing 811 812 number of dominant follicles [1, 4, 5, 15, 16, 19, 40, 41, 56] broken down to tools, shown in percentage. 813

S19 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing diameter of dominant follicles [1, 5, 15, 16] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S20 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing diameter of dominant follicles [1, 5, 15, 16] broken down to tools, shown in percentage. S21 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing mono-and multifollicular development [43, 45, 46] rate using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S22 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing mono-and multifollicular development [43, 45, 46] rate broken down to tools, shown in percentage. S23 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing ovulation rate [1, 4, 5, 19, 42-44, 46, 56] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S24 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing ovulation rate [1, 4, 5, 19, 42-44, 46, 56] broken down to tools, shown in percentage. S25 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing pregnancy rate [4-6, 15, 16, 19, 40, 42, 43, 45, 56] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

S26 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing pregnancy rate [4-6, 15, 16, 19, 40, 42, 43, 45, 56] broken down to tools, shown in percentage. S27 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing single and multiple pregnancy rate [6, 16, 19, 40, 41, 45, 56] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S28 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing single and multiple pregnancy rate [6, 16, 19, 40, 41, 45, 56] broken down to tools, shown in percentage. S29 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing rate of miscarriage [6, 16, 43, 56] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S30 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing rate of miscarriage [6, 16, 43, 56] broken down to tools, shown in percentage. S31 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing resistance index (RI) of subendometrial arteries [1, 15, 19] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S32 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing resistance index (RI) of subendometrial arteries [1, 15, 19] broken down to tools, shown in percentage. S33 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing pulsatility index (PI) of subendometrial arteries [1, 15, 19] using the revised tool for

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S34 Fig. Risk of bias assessment of the studies included in the meta-analysis assessing pulsatility index (PI) of subendometrial arteries [1, 15, 19] broken down to tools, shown in percentage. S35 Fig. Risk of bias assessment of the studies included in the systematic review assessing rate of endometrial thickness (ET) [15, 42, 47-49, 51-55, 57] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S36 Fig. Risk of bias assessment of the studies included in the systematic review assessing rate of endometrial thickness (ET) [15, 42, 47-49, 51-55, 57] broken down to tools, shown in percentage. S37 Fig. Risk of bias assessment of the studies included in the systematic review assessing endometrial volume (EV) [1, 5] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S38 Fig. Risk of bias assessment of the studies included in the systematic review assessing endometrial volume (EV) [1, 5] broken down to tools, shown in percentage. S39 Fig. Risk of bias assessment of the studies included in the systematic review assessing endometrial pattern and/or echogenicity [1, 42, 48] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S40 Fig. Risk of bias assessment of the studies included in the systematic review assessing endometrial pattern and/or echogenicity [1, 42, 48] broken down to tools, shown in percentage.

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

S41 Fig. Risk of bias assessment of the studies included in the systematic review assessing rate of number of dominant follicles [47, 49, 51-54, 57] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S42 Fig. Risk of bias assessment of the studies included in the systematic review assessing rate of number of dominant follicles [47, 49, 51-54, 57] broken down to tools, shown in percentage. S43 Fig. Risk of bias assessment of the studies included in the systematic review assessing rate of diameter of dominant follicles [47, 54] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S44 Fig. Risk of bias assessment of the studies included in the systematic review assessing rate of diameter of dominant follicles [47, 54] broken down to tools, shown in percentage. S45 Fig. Risk of bias assessment of the studies included in the systematic review assessing monofollicular development cycles [54, 55] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S46 Fig. Risk of bias assessment of the studies included in the systematic review assessing monofollicular development cycles [54, 55] broken down to tools, shown in percentage. S47 Fig. Risk of bias assessment of the studies included in the systematic review assessing ovulation rate [48, 50-53, 55] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

S48 Fig. Risk of bias assessment of the studies included in the systematic review assessing ovulation rate [48, 50-53, 55] broken down to tools, shown in percentage. S49 Fig. Risk of bias assessment of the studies included in the systematic review assessing pregnancy rate [47-55, 57] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S50 Fig. Risk of bias assessment of the studies included in the systematic review assessing pregnancy rate [47-55, 57] broken down to tools, shown in percentage. S51 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of multiple pregnancies [49-52, 57] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S52 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of multiple pregnancies [49-52, 57] broken down to tools, shown in percentage. S53 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of miscarriages [47, 49-52, 54] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S54 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of miscarriages [47, 49-52, 54] broken down to tools, shown in percentage. S55 Fig. Risk of bias assessment of the studies included in the systematic review assessing live birth rate [48-52, 56] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

S56 Fig. Risk of bias assessment of the studies included in the systematic review assessing live birth rate [48-52, 56] broken down to tools, shown in percentage. S57 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of ectopic pregnancies [6] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S58 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of ectopic pregnancies [6] broken down to tools, shown in percentage. S59 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of fetal anomalies [48, 50, 52, 54, 56] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S60 Fig. Risk of bias assessment of the studies included in the systematic review assessing number of fetal anomalies [48, 50, 52, 54, 56] broken down to tools, shown in percentage. S61 Fig. Risk of bias assessment of the studies included in the systematic review assessing endometrial vascularization index (VI), flow index (FI), vascularization flow index (VFI) and detection rate of endometrial-subendometrial blood flow [1, 5, 19] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S62 Fig. Risk of bias assessment of the studies included in the systematic review assessing endometrial vascularization index (VI), flow index (FI), vascularization flow index (VFI) detection rate of endometrial-subendometrial blood flow [1, 5, 19] broken down to tools, shown in percentage.

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

S63 Fig. Risk of bias assessment of the studies included in the systematic review assessing systolic velocity (SV)/diastolic velocity (DV) of subendometrial arteries [15] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S64 Fig. Risk of bias assessment of the studies included in the systematic review assessing systolic velocity (SV)/diastolic velocity (DV) of subendometrial arteries [15] broken down to tools, shown in percentage. S65 Fig. Risk of bias assessment of the studies included in the systematic review assessing resistance index (RI) and pulsatility index (PI) of uterine arteries [1, 5] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S66 Fig. Risk of bias assessment of the studies included in the systematic review assessing resistance index (RI) and pulsatility index (PI) of uterine arteries [1, 5] broken down to tools, shown in percentage. S67 Fig. Risk of bias assessment of the studies included in the systematic review assessing vascular endothelial growth factor (VEGF) and/or integrin alpha vß3 [5, 15] using the revised tool for assessing risk of bias in randomized trials (Rob 2). Legend: +: low risk; !: some concerns; -: high risk S68 Fig. Risk of bias assessment of the studies included in the systematic review assessing vascular endothelial growth factor (VEGF) and/or integrin alpha vß3 [5, 15] broken down to tools, shown in percentage. S69 Fig. Risk of bias assessment of the studies included in the systematic review assessing resistance index (RI) and pulsatility index (PI) of subendometrial arteries [57]

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

using the revised tool for assessing risk of bias in randomized trials (Rob 2) Legend: +: low risk; !: some concerns; -: high risk S70 Fig. Risk of bias assessment of the studies included in the systematic review assessing resistance index (RI) and pulsatility index (PI) of subendometrial arteries [57] broken down to tools, shown in percentage. Legend: +: low risk; !: some concerns; -: high risk

974

975


976

977

978

Fig 1. PRISMA (Page et al., 2021) flow diagram


PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources



\*\*If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

## Figure

Fig 2. Forest plots for the following outcomes: A) endometrial thickness (ET) - all patients; B) ovulation rate; C) pregnancy rate - all patients



20,									
		LE	group	CC	group				
Study	Comment	Events	Total	Events	Total	Odds Ratio	OR	95% CI	Weight
Wang 2019		80	120	80	119		0.97	[0.57; 1.67]	14.50%
Wang 2021		57	90	55	90	- <del>(a )</del>	1.10	[0.60; 2.01]	13.29%
Selim 2012		72	110	64	110	<del>-   10  </del>	1.36	[0.79; 2.35]	14.37%
Elsedeek 2011		41	62	35	62	- <del>10</del>	1.51	[0.73; 3.12]	11.18%
Kar 2012		38	52	31	51	+++	1.75	[0.76; 4.02]	9.67%
Atay 2006		42	51	35	55	×	2.67	[1.08; 6.60]	8.74%
Khakwani 2022		22	39	12	39		2.91	[1.15; 7.37]	8.46%
Dehbashi 2009		30	50	16	50		3.19	[1.40; 7.24]	9.82%
Zafar 2021		172	180	150	180	*	4.30	[1.91; 9.67]	9.95%
Random effects model		554	754	478	756	-	1.80	[1.21; 2.69]	100.00%
Prediction interval						_		[0.69; 4.69]	
Heterogeneity: I2 = 51% (0)	%: 77%], t <sup>2</sup> = 0	13, p = 0.0	38						
Test for overall effect: $t_0 = 3.38$ ( $p = 0.010$ )						0.2 0.5 1 2 5			

Prefers clomiphene citrate Prefers letrozole

LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; OR-odds ratio; CI-confidence interval; p-p-value

## Figure

B)

Fig 3. Forest plots for subendomendometrial circulation: A) resistance index (RI) of subendometrial arteries; B) pulsatility index (PI) of subendometrial arteries

A) LE group CC group Mean Difference SD SD MD 95% CI Study Mean Weight Mean N Wang 2019 0.10 80 0.80 0.10 -0.20[-0.23; -0.17] 34.49% 80 0.60 Al-Obaidi 2019 40 0.50 0.08 40 0.66 0.15 -0.16[-0.21; -0.11] 28.71% Selim 2012 \* 110 0.76 0.08 110 0.86 0.08 -0.11[-0.13; -0.09] 36.80% Random effects model 230 230 -0.15 [-0.27; -0.04] 100.00% -0.2 -0.1 0 0.1 0.2 Heterogeneity:  $I^2 = 92\%$  [79%; 97%],  $\tau^2 < 0.01$ ,  $\rho < 0.001$ Test for overall effect:  $t_2 = -5.64$  (p = 0.030) Prefers clomiphene citrate Prefers letrozole B) LE group CC group nt %

Study	N	Mean	SD	N	Mean	SD	Mean Difference	MD	95% CI	Weight	
Selim 2012 *	110	1.35	0.48	110	1.76	0.61	i	-0.41	[-0.55; -0.26]	32.75%	
Al-Obaidi 2019	40	0.74	0.34	40	0.96	0.34	<del></del>	-0.22	[-0.37; -0.07]	32.58%	
Wang 2019	80	1.30	0.20	80	1.20	0.30	<del></del>	0.10	[0.02; 0.18]	34.67%	
Random effects model	230			230				-0.17	[-0.81; 0.47]	100.00%	
Heterogeneity: $I^2$ = 95% [89%; 98%], $\tau^2$ = 0.06, $p$ < 0.001						-0.5 0 0.5					
Test for overall effect: $t_2 = -1.14$ ( $p = 0.372$ )					Profess claminhana citrata - Profess latrazala						

Prefers clomiphene citrate Prefers letrozole

LE-letrozole; CC-clomiphene citrate; N-number of patients; MD-mean difference; SD-standard deviation; CI-confidence interval; p-p-value

## Figure